Shanghai Securities News (reporter Liu Yipeng) "At the beginning of this year, the first stem cell drug in China was approved for listing, marking a new stage of standardization and standardization of the industry. At present, many stem cell varieties have entered phase II and phase III clinical trials. Hainan Boao Music City International Medical Tourism Pioneer Zone has passed the policy of" first trial first ", providing an important test ground for clinical transformation." On April 25, at the 2025 Boao Stem Cell Industry Conference, Wang Guangji, an academician of the CAE Member and professor of China Pharmaceutical University, said in an exclusive interview with reporters from Shanghai Securities News that the core of stem cell therapy is safe, effective and quality controllable, and only through strict standards. Only the stem cell products produced in chemical production, reviewed by the drug supervision department and clinically verified can truly benefit patients.

When it comes to the direction of clinical translation of stem cell therapy in the next 2 to 3 years, Wang Guangji said that areas such as immune regulation, tissue repair, and anti-inflammatory therapy are worth paying attention to. For example, in the treatment of liver disease, the essence is to suppress inflammatory reactions, and stem cells have great potential in this type of indication. However, he also reminded that currently approved products are still concentrated in limited diseases, and clinical applications need to be accurately targeted. "Stem cells are not a panacea, and the mechanism and indications must be clarified.

In response to the challenges of industrialization, Wang Guangji bluntly stated that "safety is the lifeline". It is reported that in the three stem cell therapy projects implemented in the Boao Lecheng International Medical Tourism Pilot Zone in Hainan, patient screening is strictly limited to "moderate to severe but not endangered cases" to ensure that the efficacy is verifiable and the risks are controllable.

At the same time, Wang Guangji called for the establishment of a national policy framework to prevent cells from unknown or contaminated sources from entering the market. "People who inject stem cells must be clear about what they are injecting.

Wang Guangji holds a cautiously optimistic attitude towards the application of stem cells in the field of anti-aging. The anti-aging effect needs to be scientifically verified, and the efficacy cannot be deified. He believes that with the advancement of industrialization, the cost of single treatment with stem cells will gradually decrease. "In the future, it may cover a wider population, but the premise is to establish universal safety standards.

In response to the chaos in the industry, Wang Guangji reiterated the concept of "precision treatment". It is necessary to clarify the in vivo processes and mechanisms of action of stem cells, rather than making vague claims of 'reversing aging', "said Wang Guangji.